skip to main content

Spring, 2013

Football fundraiser

U-M Football Event Supports Cancer Research

Michigan Medicine, in partnership with Michigan Athletics, is gearing up for an event that combines Michigan football and U-M's cancer research.

The Michigan Men's Football Experience runs June 6-7 and is still registering participants.

Circulating cancer cells

Capturing circulating cancer cells could provide insights into how disease spreads

A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells that carry cancer around the body through the bloodstream.

Engineering and medical researchers at the University of Michigan have devised such a set-up, which they say takes advantage of cancer cells' stronger drive to settle and bind compared with normal blood cells.

New technique sheds light on RNA

U-M researchers develop method that could enhance gene sequencing data

When researchers sequence the RNA of cancer cells, they can compare it to normal cells and see where there is more RNA. That can help lead them to the gene or protein that might be triggering the cancer.

Gene sequencing and cancer

Gene sequencing program helps identify cancer mutations

image of patient sitting in a waiting room
Photo credit: Siri Stafford/ Photodisc/ThinkStock

MI-ONCOSEQ effort gives researchers new leads to improve treatments

It started with a 44-year-old woman with solitary fibrous tumor, a rare cancer seen in only a few hundred people each year.

Patient to philanthropist

Although just out of high school, Matt Vogel left a lasting legacy for others facing rare skull base tumors

In the years since Matthew Vogel died, part of him has continued on at the University of Michigan.

A native of Kansas who was studying at St. Olaf College in Minnesota, Matt lost his life to sinonasal undifferentiated cancer, or SNUC, in 1997. But his final gift continues to provide hope for others like him, others who will get the difficult news that they have a rare and little-understood skull base tumor with a poor prognosis.

Herceptin and breast cancer

U-M study challenges notion of using Herceptin only for HER2-positive breast cancer

Breast cancer stem cells express HER2, even in 'negative' tumors, study finds

New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative -- and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.

A Message from our Director, Spring 2013

Welcome to the spring edition of the University of Michigan Comprehensive Cancer Center's electronic newsletter. I'm pleased to be able to share with you some of the interesting and exciting ways that the UMCCC continues to make great strides in understanding, diagnosing, preventing and treating cancer.